Created On: 2020-07-15
Record Count: 19
- Technical Know How
- Drug Discovery
- HIV / AIDs
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 27803
LAG-3 is a checkpoint protein expressed on the surface of certain cells of the immune system. LAG-3 (lymphocyte-activation gene 3) modulates signaling between immune cells and their targets. When LAG-3 is activated, the immune response is suppressed. Antibodies that block LAG-3 can block this inhibitory signal, thereby boosting the immune systemâ€™s response against cancer cells. LAG-3 acts synergistically with other checkpoint modulators. This suggests antibodies against LAG-3 may be valuable as combination therapies.
TIM-3 is a checkpoint receptor found on certain immune cells. TIM-3 stands for T-cell immunoglobulin and mucin domain-3. To prevent hyperactivation, natural ligands binding to TIM-3 reduce the activity of these immune cells. In some types of cancer, T cells express elevated levels of TIM-3, which results in excessive immune suppression. Blocking TIM-3 could stimulate immune responses and promote immune-mediated clearing of cancer cells. TIM-3 antibodies may have a role as a monotherapy and hold great potential in combination therapy, since they may help overcome resistance that patients may develop against other therapeutics.
IPSCIO Record ID: 184504
The original agreement entered into a broad, global alliance with the parties to discover, develop and commercialize novel immuno-therapeutics using the antibody platforms. The collaboration was initially focused on four CPM programs targeting GITR, OX40, TIM-3 and LAG-3, and in November 2015, was expanded by adding three novel undisclosed CPM targets.
GITR is an immune checkpoint agonist, one of a class of receptors that amplify the immune systemâ€™s response to cancer. GITR (glucocorticoid-induced TNFR-related protein) is a receptor expressed on select populations of T cells. Activation of GITR leads to a more powerful anti-tumor inflammatory response, increased production of inflammatory signaling molecules and increased resistance to immunosuppression.
OX40 (also known as CD134 and TNFRSF4), a member of the TNFR super-family, is an immune-response-enhancing receptor found on activated T cells. OX40 promotes proliferation of these activated T cells and prevents the immunosuppressive activity of inhibitory T cells. We believe that antibodies that activate OX40 may help increase immune system activity through both of these mechanisms. Furthermore, OX40 antibodies have the potential to work alone or in combination with other therapeutics. Combining with another agonist checkpoint antibody, which provides different, yet complementary signaling attributes may further augment anti-tumor responses.
IPSCIO Record ID: 226529
IPSCIO Record ID: 195780
Licensor owns the rights to Patent Application Serial No. 62/478520 filed 03-29-17 â€œMethods of Re-Activating Dormant Memory Cells with Anticancer Activityâ€ and commercially named â€œMemoryMuneâ€.
The patent licensed provides means to recapitulate a natural immune response ex vivo through activation of innate immune cells, and subsequently utilizing products generated by said cells to stimulate adaptive immune cells to acquire ability to induce killing or inhibiting proliferation of cells expressing oncogenic transformations. In one embodiment of the invention, innate immune cells are activated with stimuli capable of inducing production of cytokines associated with induction of immunity to intracellular abnormalities; said cytokines are further administered to adaptive immune cells in a patient in need of treatment.
Licensee intends to develop products that can be used together to attack cancer at different levels, as well as to be used alone or in combination with existing therapies.
Developing the novel immunological use of mifepristone in the area of oncology adds another weapon in the fight against cancer using the patientâ€™s own immune system. Natural killer cells are a unique arm of the immune system that is capable of killing cancer cells without prior sensitization. The findings that mifepristone is capable of reducing cancer associated suppression of the natural killer cell compartment, we believe, positions mifepristone as a potentially valuable therapeutic in utilization of the immune system to kill tumors.
IPSCIO Record ID: 296181
The November amendment adds an additional dual-reactive antibody product candidate.
The AnaptysBio platform offers unmatched capabilities in antibody discovery, generation and optimization, and we are excited about the potential for these programs. We look forward to working with the AnaptysBio team to develop novel immuno-oncology-based approaches to a variety of tumors.
IPSCIO Record ID: 26237
Patent: Antigen binding proteins that bind PD-L1
IPSCIO Record ID: 255299
MGD013 is a first-in-class bispecific DART molecule designed to provide coordinate blockade of two immune checkpoint molecules expressed on T cells, PD-1 and LAG-3, for the potential treatment of a range of solid tumors and hematological malignancies.
IPSCIO Record ID: 256218
Eshhar patents: US 5,906,936
US 7,741,465, Eshhar et al
Eshhar-NIH patent: US 8,211,422, Eshhar et al
Eshhar-NIH pending application: [US 13/281,560, Eshhar et al
KTE-C19 is an anti-CD19 CAR T cell therapy. CD19 is a protein expressed on the cell surface of B cell lymphomas and leukemias.
IPSCIO Record ID: 415
A patent application has been filed for the technology entitled Combination Immunogene Therapy, United States Patent Application No. 09/826,025. The standard approach in utilizing gene therapy to combat cancer has been to attempt to replace defective genes in cancer cells, which has proven to be impractical because of the number of genes involved. The combination gene therapy technology invented by Dr. Chang uses GM-CSF (a granulocyte macrophage colony stimulating factor) and B7-2 (a T-cell co-stimulating factor) to both build the bodyâ€™s immune system and destroy cancer cells. The treatment involves injecting the patient with two genes in one virus carrying a combination of B7-2 and GM-CSF. Our technology, which shows potential for fighting cancer by enhancing oneâ€™s immune system and thereby increasing the number of cells that naturally destroy cancer, has proven effective in eradicating experimental human brain tumors implanted in mice and has undergone Phase 1 clinical trials in Canada.
IPSCIO Record ID: 280819
For the Commercial License, Licensor grants an exclusive, worldwide license to make, have made, use, have used, sell, have sold, offer for sale, import and have imported Licensed Products for use in the Field directed to such Licensee Target under Licensor Background Inventions, and under Licensors rights in all Patent Rights and Collaboration Inventions and Collaboration Material pertaining to such Licensee Target and Licensed Products, or the uses thereof in the Field.
The two companies will collaborate on the development of human antibodies for the treatment of cancer.
IPSCIO Record ID: 263928
IPSCIO Record ID: 28127
IPSCIO Record ID: 3285
Low-grade or follicular CD20-positive non-Hodgkin's lymphoma as a single-agent therapy in patients whose disease recurred or did not respond to initial treatment
Follicular CD20-positive non-Hodgkin's lymphoma as an initial treatment with chemotherapy, and in patients whose initial treatment was successful, as a single-agent follow-up therapy
Low-grade or follicular CD20-positive non-Hodgkin's lymphoma as a single-agent follow-up therapy for patients who responded to initial treatment with CVP chemotherapy
IPSCIO Record ID: 256279
Licensor grants a worldwide, co-exclusive, with Licensor, right and license, with the right to grant sublicenses, under the Licensor Collaboration Technology to make, have made, use, offer for sale, sell, and import any product that is not a BiTE Product for any use in humans.
BiTE Molecule means a polypeptide comprising a bi-specific Single Chain Antibody binding to T-cells.
Target means a cell-surface antigen. The list of proprietary targets is: epha2, alpha – V, and, beta-3.
BiTE(R) molecules are part of a novel class of antibody derivatives that may have the potential to selectively direct and activate the human immune system to act against cancer cells. This action is believed to occur as a result of the molecule's stimulation of T cells to target and destroy cancer cells that express a specific antigen.
BiTE molecule targeting CD19 is for the potential treatment of certain lymphomas.
IPSCIO Record ID: 211579
Antibodies targeting PD-1 have shown clinical efficacy in the treatment of various tumors. These antibodies act as checkpoint inhibitors, releasing the â€œbrakesâ€ on the immune system that are often imposed by tumors as a means to evade immune detection.
IPSCIO Record ID: 27478
IPSCIO Record ID: 110461
Licensor grants to the Licensee the authority to make application for Patents, in the name of the Licensor.
IPSCIO Record ID: 4616
EVO 011 is a monoclonal antibody that is a receptor blocker. EVO 011 stops cancer cell proliferation, and inhibits cancer cells from metasizing, blocking Angiogenesis II. It significantly reduces cancer invasion and will be used as an adjunct therapy. This drug may also have a use in cardiovascular disease.
most forms of cancer.
IPSCIO Record ID: 209514
For inventions which are incremental improvements dominated by existing patents or pending patent applications for which Sponsor holds a license, Licensor grants to Sponsor an option to secure an exclusive license with the right to make, use and sell, have made, have used, import and offer for sale the claimed invention conceived or reduced to practice in the conduct of the Project.
The Licensor retains a perpetual, non-exclusive right to use the licensed property, product, procedure or process and to use the licensed technology for basic and clinical research, and the educational purposes of the Licensor, and not for any commercial purpose.
The knowledge is relating to a project entitled 'Use of heat shock proteins for the development of therapeutic and prophylactic vaccines for cancer and infectious diseases'.
Heat shock proteins, also known as HSPs, are also called stress proteins. HSPs are a group of proteins that are induced when a cell undergoes various types of environmental stresses like heat, cold and oxygen deprivation. HSPs are present in all cells in all life forms from bacteria to mammals, and their structure and function are similar across these diverse life forms. Under normal conditions, heat shock proteins play a major role in transporting fragments of proteins called peptides, including antigenic peptides, within a cell, and are thus called â€œchaperones.â€ Antigenic peptides are those portions of a protein that stimulate immune response when recognized by the immune system. Because HSPs chaperone peptides within the cell, they bind a broad array of antigenic peptides and facilitate their recognition by the immune system. Thus, HSPs help present the antigenic â€œfingerprintâ€ of the cell to the immune system.